Track topics on Twitter Track topics that are important to you
The chances of Johnson & Johnson’s rheumatoid arthritis drug sirukumab getting approved in the US look slim, after the FDA’s expert advisers raised concerns about its safety. The regulator’s Arthritis Advisory Committee voted 12 to 1 aga...
Original Article: FDA advisers reject J&J rheumatoid arthritis drugNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...